Navigation Links
Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
Date:7/13/2008

SHANGHAI, China, July 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that Dr. Richard M. Soll has joined WuXi PharmaTech as Vice President of Medicinal Chemistry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

As a pharmaceutical veteran, Dr. Soll brings over 25 years of scientific experience and proven leadership capability to his new role in WuXi. Prior to joining WuXi, Dr. Soll worked at TargeGen Inc., a San Diego based biotechnology company, as Vice President of Research and Development and Chief Scientific Officer from March 2003 to March 2008. Before joining TargeGen, Dr. Soll held senior positions with increasing responsibilities at Ontogen Corporation and 3-Dimensional Pharmaceutical, Inc.

Dr. Soll is well recognized and respected for his scientific acuity from the academic and industry circles. Amongst his most recent achievements are first-in-class drug development nomination candidates and clinical development drugs for potential treatment for cancer, thrombosis, ocular disease, inflammation, edema and myeloproliferative disorders.

As the Vice President of Medicinal Chemistry Dr. Soll will help the company to expand and strengthen its medicinal chemistry services platform. Dr. Soll will report directly to Dr. Shuhui Chen, Chief Scientific Officer of WuXi PharmaTech.

"I am very excited to welcome Dr. Soll on board to lead and expand our already strong medicinal chemistry unit," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Previously a customer of WuXi, Rich has a unique perspective on how to maximize service value creation for clients. His broad experience in the pharmaceutical industry and proven track record as a leader make him an ideal fit for the organization. I am confident that under his leadership our medicinal chemistry service capability will be stronger and further integrated with those of other services."

Dr. Soll received his B.S. in Chemistry from the University of Massachusetts, Massachusetts and his Ph.D. in Chemistry from Dartmouth College, New Hampshire. He was also a chemistry post-doctoral fellow at Harvard University with Professor E. J. Corey.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cohera Medical Names Richard L. Wonsettler as Companys First CFO
2. AST Awards Richard N. Fine, M.D. 2008 Ernest Hodge Distinguished Achievement Award
3. Chicago Mayor Richard M. Daley to Address the 7th Annual Compliance and Ethics Institute
4. MultiVu Video Feed: Richard Simmons and Ocean Spray Team-Up to Solve
5. Stop Obesity Alliance, Chair Dr. Richard H. Carmona, National Opinion Research Center Reveal Findings of Survey Showing Employer Concern About Health, Financial Costs of Obesity
6. Veterans Honor Dr. Richard Merkin During Research Week
7. Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
8. Richard T. Clark Elected PhRMA Board Chairman
9. Danny Calegari Appointed the Richard Merkin Distinguished Professor of Mathematics at the California Institute of Technology
10. Kevin Richardson Named Vice President, Sales, National & Multi-State Business for Kaiser Permanente
11. AACN Applauds Senator Richard Durbin for Introducing the Troops to Nurse Teachers Act of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Peoria, IL (PRWEB) , ... May 22, 2017 ... ... HealthCare, is part of a larger group investing in InsightRX, an early stage ... a patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund ...
(Date:5/21/2017)... FL (PRWEB) , ... May 20, 2017 , ... Pot. ... it, find it, review it, and share its attributes like never before. More than ... directory to connect cannabis enthusiasts to stores, strains, products – and for the first ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... longer than six months since you've seen a dentist, it's time for a ... and getting x-rays once per year. , Dental checkups are a relatively easy ...
(Date:5/19/2017)... ... May 19, 2017 , ... Springfield, Vermont-based law firm ... Titled " Ten Good Reasons To Hire An Experienced Personal Injury Attorney, " the ... an accident or injury. As the article says. if someone is injured due ...
(Date:5/19/2017)... ... 19, 2017 , ... As a groundbreaking surgeon on the frontline of prostate ... screenings. Early detection of the disease, he says, can make a world of difference. ... , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: